Pulgar B Dahiana, Yáñez B Nicolás, Ortega G Francisco
Centro de Oncología y radioterapia HRT, Facultad de Medicina, Universidad Católica del Maule, Chile.
Rev Med Chil. 2019 Jul;147(7):887-890. doi: 10.4067/S0034-98872019000700887.
The use of systemic chemotherapy has survival and palliation benefits in oncological patients. Mortality at 30 days after the administration of systemic chemotherapy is considered as a quality and safety indicator of oncological patient care. The international mortality threshold is 5%, which is the figure used to compare institutions.
To assess mortality at 30 days after the administration of ambulatory systemic chemotherapy in a regional referral center in adult cancer patients.
Retrospective observational study of patients receiving ambulatory systemic chemotherapy in the oncology service of a regional public hospital during 2018. The 30-day mortality rate was calculated. Demographic characteristics, baseline disease and the treatment received were recorded.
During the study period, 690 patients received ambulatory systemic chemotherapy. Chemotherapy was palliative in 76% of patients and 53% received a first line treatment. Seventeen (2.5%) died within 30 days of treatment administration. Nine deaths (52.9%) were definitely related to treatment and sepsis was the most frequent cause.
Our mortality rates are similar to international data. This type of audit reviews local outcomes and identifies factors contributing to mortality aiming to improve standards of care.
全身化疗在肿瘤患者中具有生存和姑息治疗益处。全身化疗给药后30天的死亡率被视为肿瘤患者护理质量和安全性的指标。国际死亡率阈值为5%，该数值用于机构间比较。
评估在一个成人癌症患者区域转诊中心进行门诊全身化疗给药后30天的死亡率。
对2018年期间在一家区域公立医院肿瘤科接受门诊全身化疗的患者进行回顾性观察研究。计算30天死亡率。记录人口统计学特征、基线疾病和接受的治疗。
在研究期间，690例患者接受了门诊全身化疗。76%的患者化疗为姑息性，53%接受一线治疗。17例（2.5%）在治疗给药后30天内死亡。9例死亡（52.9%）肯定与治疗相关，败血症是最常见原因。
我们的死亡率与国际数据相似。这种类型的审核可评估当地结果并确定导致死亡的因素，旨在提高护理标准。
